Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials
抗致瘤素 M 单克隆抗体在类风湿性关节炎中的安全性、耐受性、药代动力学和药效学：来自 II 期随机、安慰剂对照试验的结果
阅读：5
作者：Ernest H Choy, Marina Bendit, Dana McAleer, Feng Liu, Maria Feeney, Sara Brett, Stefano Zamuner, Andrea Campanile, John Toso
Conclusion
Our data highlighted the importance of binding affinity and off-rate effect of a mAb to fully neutralize the target and how this may influence its efficacy and potentially worsen disease activity. Using an anti-OSM mAb with high affinity should test this hypothesis and examine the potential of OSM as a therapeutic target in RA.
Trial registration
ClinicalTrials.gov no: NCT00674635.
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。
2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。
4、投稿及合作请联系：info@biocloudy.com。
